BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Company Information
About this company
Key people
Anna Guinot Aguado
Member Investment Management Team, Investment Analyst
Jordan Baumhardt
Member of Investment Management Team, Investment Analyst
Maurizio Bernasconi
Deputy Head of the Investment Management Team, Investment Analyst
Christian Koch
Head of the Investment Management Team
Kyle Rasbach
Member of Investment Management Team, Head US Research and Investment Analyst
Thomas Von Planta
Independent Chairman of the Board
Clive A. Meanwell
Independent Vice Chairman of the Board
Laura Jean Hamill
Independent Director
Pearl S. Huang
Independent Director
Camilla Soenderby
Independent Director
Click to see more
Key facts
- Shares in issue55.40m
- EPICBION
- ISINCH0038389992
- LocationSwitzerland
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capCHF 2.57bn
- Employees73
- ExchangeSIX Swiss Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.